An Observational Study to Collect High Resolution 12-Lead Electrocardiogram (ECG) Data for the Development of an ECG Library to Support the Development of a Tool to Monitor Disease Progression, Gather Patient Perspectives on Standard of Care Heart Failure Procedures and Facilitate Familiarity with the Clinical Trial Environment in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Maximum Age: 80
Healthy Volunteers: f
View:

• Male or female participants aged 45 to 80 years (inclusive) at the date of signing the informed consent.

• Diagnosed with heart failure.

• Able and willing to provide informed consent to participate.

Locations
Other Locations
United Kingdom
Richmond Pharmacology
RECRUITING
London
Richmond Pharmacology
RECRUITING
London
Contact Information
Primary
Volunteer Recruitment Team
volunteer@richmondpharmacology.com
+44 (0) 207 042 5800
Time Frame
Start Date: 2025-02-05
Estimated Completion Date: 2027-02-21
Participants
Target number of participants: 1000
Treatments
Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Study to Collect High Resolution 12-Lead Electrocardiogram (ECG) Data for the Development of an ECG Library to Support the Development of a Tool to Monitor Disease Progression, Gather Patient Perspectives on Standard of Care Heart Failure Procedures and Facilitate Familiarity with the Clinical Trial Environment in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Sponsors
Leads: Richmond Research Institute

This content was sourced from clinicaltrials.gov